source
- RA Capital leads $175 million round for Oak Hill Bio to revive Roche’s Angelman syndrome drugRA Capital and other investors have committed $175 million to Oak Hill Bio, a new biotech aiming to revive a previously shelved experimental therapy for Angelman syndrome originally developed by Ro…
- Argenx to acquire Forte Biosciences for $2.2 billion, bolstering its autoimmune drug pipelineArgenx announced it will purchase Dallas-based Forte Biosciences for $2.2 billion in cash. The transaction values Forte at $77 per share, a 41 percent premium to its closing price on Friday. The a…